Aktienanalyse zu Novocure Ltd (NVCR)NVCRNovocure Ltd

NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Currently, Novocure Ltd (NVCR) is not a strong buy due to its recent price decline and technical indicators. The current price is $14.07, and the RSI is at 35.462, indicating potential oversold conditions but also a lack of upward momentum. The forward P/E ratio is extremely high at 909.09, suggesting that the stock is overvalued based on future earnings expectations. While the company reported a 16% year-over-year revenue increase to $183.6 million in Q2 2026, the net income remains negative at -$15.65 million for the same quarter. The main risk is the stock's recent performance, with a 5-day change of -3.50% and a year-to-date change of +7.24%, indicating volatility.

6 analysts cover NVCR: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 23.58.